ALNY Trading Analysis - 10/23/2026 04:17 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for Alnylam Pharmaceuticals (ALNY) includes the following thematic headlines that may relate to the data period:

• ALNY secures FDA expanded approval for RNAi therapy in cardio-metabolic indication (mid-2026) — potential long-term revenue catalyst.
• Phase III readout for investigational polyneuropathy asset shows mixed efficacy — biotech volatility typical around binary events.
• Institutional holdings remain elevated (~95%) with steady accumulation through Q3 2026.
• No confirmed near-term earnings date in provided data; fiscal year end listed as 2025-12-01, suggesting annual reporting cycle later than Oct 2026.
• Broad biotech sector pressured by rate-sensitive small/mid-cap rotation, consistent with ALNY's drawdown from 52-week high of $485.36 to current ~$225.

Context: These items suggest fundamental promise but sector/macro headwinds; they align with the technical picture of a stock well below prior highs and trading in a compressed range, with balanced options sentiment rather than conviction-driven directional flow.

Fundamental Analysis

Based strictly on the embedded FUNDAMENTALS data for ALNY:

• Trailing P/E: 41.70; Trailing EPS: $5.53 — valuation elevated vs. typical pharma peers but common for clinical-stage biotech with platform potential.
• Market Cap: $30.11B; Shares Outstanding: 133.81M; Institutional Ownership: 95.01% — high institutional sponsorship.
• Dividend Yield: 0.00%; No dividend declared (ex-dividend null).
• Beta: 0.94 — slightly less volatile than broad market.
• 52-Week High: $485.36; 52-Week Low: $197.81 — current price ~$225 implies deep retracement from highs (~53% below high).
• Historical Volatility: 41.63%; Average Volume: 1.25M shares.
• PEG Ratio, Forward P/E, Profit Margins, ROE, Debt/Equity, Free Cash Flow, Revenue Growth, Total Revenue: all null/not provided — cannot assess growth or margin trajectory from data.
• Analyst consensus and target mean price: null — no street target in data.

Fundamentals show a high-institution-owned, non-profitable-dividend name with rich trailing multiple and no provided growth/margin proof. This diverges from the technical posture (price below all major SMAs, balanced sentiment) in that fundamentals alone do not explain the 50% drawdown — likely sentiment/sector driven, not captured in static fundamentals.

Current Market Position

From DAILY and MINUTE bars: Current price (2026-10-22 close) is $225.75. Minute bars show 2026-10-23 15:50 close at $225.00, with intraday range $224.27–$225.00 in final 20 mins and steady tick-up from $224.28 at 15:30. First minute 2026-10-22 09:30 open $224.92, high $225.95, low $224.01, close $225.23.

Recent daily action: 2026-10-21 close $225.27, 2026-10-22 close $225.75 (volume 1.72M vs 20d avg 0.89M — above average). 30-day range high $257.27, low $215.46.

Intraday momentum on 2026-10-23 afternoon is marginally positive (higher lows $224.28 → $225.00) but within narrow band; no breakout confirmed.

Technical Analysis

SMA alignment: Price $225.75 < SMA5 $229.29 < SMA20 $232.40 < SMA50 $239.17 — bearish stack, no bullish crossover. RSI 55.31 neutral-positive, not overbought. MACD negative (-3.90) below signal (-3.12), histogram -0.78 = bearish momentum persisting. Bollinger mid $232.40, price beneath mid, inside bands (lower $209.95, upper $254.85) = no squeeze/expansion signal. 30d range: price at $225.75 is 24.7% above low $215.46 and 12.2% below high $257.27 — middle-lower quadrant.

True Sentiment Analysis (Delta 40-60 Options)

From TRUE SENTIMENT OPTIONS (2026-10-23 16:17): Sentiment Balanced. Call dollar vol $92,750 (59.6%), Put dollar vol $62,940 (40.4%), total $155,690. Contracts: 30 calls / 31 puts; trades: 5 call / 3 put. Only 8 of 742 options analyzed met delta filter (1.1%).

Directional conviction: Balanced, slight call-notional tilt but put contract count higher. Near-term expectation = no decisive directional bet. Divergence: Technicals bearish-stacked yet call $ vol > put $ vol — mild bullish offset vs weak SMA/MACD, but within "balanced" band.

Key Price Levels (Observational Only)